

Supplementary Table S3. Treatment Interruption by Hematological Adverse Event Type

Adverse event type	No interruption n (%)	Treatment interruption n (%)	Total
Anemia	45 (88.2)	6 (11.8)	51
Thrombocytopenia	211 (85.1)	37 (14.9)	248
Leukopenia	158 (87.8)	22 (12.2)	180
Any hematological adverse event	220 (84.9)	39 (15.1)	259

Note: Treatment interruption includes temporary interruption or permanent discontinuation of linezolid. Percentages are calculated within each adverse event category. Patients may have experienced more than one hematological adverse event.